Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?
Autore:
Piccart, MJ; Biganzoli, L; Di Leo, A;
Indirizzi:
Free Univ Brussels, Ctr Tumeurs, Assoc Hosp Bruxelles,Inst Jules Bordet, Dept Internal Med,Chemotherapy Unit, B-1000 Brussels, Belgium Free Univ Brussels Brussels Belgium B-1000 nit, B-1000 Brussels, Belgium
Titolo Testata:
EUROPEAN JOURNAL OF CANCER
, volume: 36, anno: 2000, supplemento:, 1
pagine: S4 - S10
SICI:
0959-8049(200004)36:<S4:TIOCDD>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADJUVANT CHEMOTHERAPY; STAGE-II; THERAPY;
Keywords:
dose density; dose intensity; cumulative dose; breast cancer; anthracycline; cyclophosphamide; taxanes;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Piccart, MJ Free Univ Brussels, Ctr Tumeurs, Assoc Hosp Bruxelles,Inst Jules Bordet, Dept Internal Med,Chemotherapy Unit, 1 Rue Heger Bordet, B-1000 Brussels, Belgium Free Univ Brussels 1 Rue Heger Bordet Brussels Belgium B-1000
Citazione:
M.J. Piccart et al., "The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?", EUR J CANC, 36, 2000, pp. S4-S10

Abstract

Optimising chemotherapy dose density and dose intensity are strategies aimed at improving outcomes in adjuvant therapy for patients with breast cancer. There are, in theory, at least five models allowing the delivery of a higher overall drug dose intensity. These are reviewed in this article and vary according to three main variables: the dose per course, the interval between doses and the total cumulative dose. Cyclophosphamide, anthracyclines and taxanes are among the most active agents for the treatment of breast cancer and, as such, they have been or are currently the focus of prospective, randomised clinical trials testing some of these dose-intensity models inthe adjuvant setting. The results of recent trials suggest that anthracyclines, but not cyclophosphamide, are associated with better outcomes if usedat higher doses per course and at higher cumulative doses. However, care has to be taken with premenopausal women where an increased dose of anthracycline per course but a reduced cumulative dose appears to produce a worse outcome. Moreover, decreasing the interval between doses, for anthracyclinesand cyclophosphamide, does not seem to provide, so far, additional benefits for women with locally advanced breast cancer. This approach is not feasible with docetaxel, since an increase in dose density induces unwanted side-effects. These results represent our current state of knowledge, but clinical trials are being performed to evaluate further the effect of dose intensity, dose density and cumulative dose of key therapeutic agents on patientoutcomes. (C) 2000 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 07:44:36